American Heart Journal
Volume 156, Issue 1 , Pages 85-91 , July 2008

Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy

  • Vanessa Roldán, MD, PhD

      Affiliations

    • Centro Regional de Hemodonación, University of Murcia, Murcia, Spain
    • Red de Investigación Cardiovascular RECAVA—Instituto Salud Carlos III, Madrid, Spain
    • ,
  • Francisco Marín, MD, PhD

      Affiliations

    • Red de Investigación Cardiovascular RECAVA—Instituto Salud Carlos III, Madrid, Spain
    • Department of Cardiology, Hospital General Universitario, Alicante, Spain
    • Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • Corresponding Author InformationReprint requests: Francisco Marín, MD, PhD, Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Ctra Madrid-Cartagena, 30120 El Palmar, Murcia, Spain.
    • ,
  • Juan R. Gimeno, MD, PhD

      Affiliations

    • Red de Investigación Cardiovascular RECAVA—Instituto Salud Carlos III, Madrid, Spain
    • Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Francisco Ruiz-Espejo, MD

      Affiliations

    • Red de Investigación Cardiovascular RECAVA—Instituto Salud Carlos III, Madrid, Spain
    • Department of Clinical Analysis, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Josefa González, MD

      Affiliations

    • Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Eloisa Feliu, MD, PhD

      Affiliations

    • Magnetic Resonance Unit, Inscanner, Hospital General Universitario, Alicante, Spain
    • ,
  • Antonio García-Honrubia, MD

      Affiliations

    • Department of Cardiology, Hospital General Universitario, Alicante, Spain
    • ,
  • Daniel Saura, MD

      Affiliations

    • Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Gonzalo de la Morena, MD

      Affiliations

    • Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Mariano Valdés, PhD

      Affiliations

    • Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
    • ,
  • Vicente Vicente, PhD

      Affiliations

    • Centro Regional de Hemodonación, University of Murcia, Murcia, Spain
    • Red de Investigación Cardiovascular RECAVA—Instituto Salud Carlos III, Madrid, Spain

Received 20 August 2007 ,Accepted 24 January 2008.

References 

  1. Libby P, Lee RT. Matrix matters. Circulation. 2000;102:1874–1876
  2. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res. 2002;90:520–530
  3. Jalil JE, Doering CW, Janicki JS, et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989;64:1041–1050
  4. Frohlich ED. Risk mechanisms in hypertensive heart disease. Hypertension. 1999;34(part 2):782–789
  5. Laviades C, Varo N, Fernández J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535–540
  6. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708–1715
  7. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944–1949
  8. Jordán A, Roldán V, García M, et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in congestive heart failure: relation to functional data and prognosis. J Intern Med. 2007;262:385–392
  9. Elliot P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881–1891
  10. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Eng J Med. 1987;316:780–844
  11. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–1320
  12. Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108:1455–1460
  13. Noji Y, Shimizu M, Ino H, et al. Increased circulating matrix metalloproteinase–2 in patients wit hypertrophic cardiomyopathy with systolic dysfunction. Circ J. 2004;68:355–360
  14. Fassbach M, Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Cardiol. 2005;94:328–335
  15. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation. 2002;106:416–422
  16. Maron BJ, Tholakanahalli VN, Zenovich AG, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109:984–989
  17. Briguori C, Betocchi S, Maganelli F, et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J. 2001;22:1328–1336
  18. Tsuruda T, Boerringter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91:1127–1134
  19. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260–2264
  20. Dumont CA, Monserrat Soler R, Rodríguez E, et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2007;60:15–23
  21. McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997;77:130–132
  22. Shirani J, Pick R, Roberts WC, et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiiol. 2000;35:36–44
  23. Marian AJ, Senthil V, Chen SN, et al. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol. 2006;47:827–834
  24. Yamazaki T, Lee JD, Shimizu H, et al. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail. 2004;6:41–45
  25. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure in Val-Heft. Eur Heart J. 2004;25:292–299
  26. Thaman R, Esteban MT, Barnes S, et al. Usefulness of N-terminal pro–B-type natriuretic Peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:515–519
  27. Moon JC, McKenna W, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–1571
  28. Wilson JM, Villareal RP, Hariharan R, et al. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J. 2002;29:176–180
  29. Moon JC. What is late gadolinium enhancement in hypertrophic cardiomyopathy?. Rev Esp Cardiol. 2007;60:1–4
  30. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55–62
  31. Heymans S, Lupu F, Terclavers S, et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol. 2005;166:15–25
  32. Moshal KS, Tyagi N, Moss V, et al. Early induction of matrix metalloproteinase-9 transducers signalling in human heart end stage failure. J Cell Mol Med. 2005;9:704–713
  33. Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodelling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol. 2004;44:398–405

PII: S0002-8703(08)00155-5

doi: 10.1016/j.ahj.2008.01.035

American Heart Journal
Volume 156, Issue 1 , Pages 85-91 , July 2008

Article Tools

* Image Usage & Resolution